GO
Loading...

Supreme Court Declines Review of Amgen Patent Dispute

The U.S. Supreme Court said it would not hear an appeal by drug maker Amgen that centers on how much leeway appeals courts should have in overruling the findings of lower courts in patent cases.

In the latest in a series of major patent cases, the high court declined to review whether a specialized patent appeals court in Washington, D.C., can scrap key patent interpretations made by district court judges during an appeal.

The case is part of Amgen's long-standing patent battle to prevent two other drugmakers from selling a product that would compete with its widely used Epogen anemia treatment.

Amgen in 1997 sued the drugmakers, Hoechst Marion Roussel and Transkaryotic Therapies, in U.S. District Court for the District of Massachusetts, alleging their planned product infringed five Amgen patents. Hoechst, after a merger, is now part of Paris-based Sanofi-Aventis. Transkaryotic has since been acquired by Shire Pharmaceuticals Group of Britain.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Mad Money's Jim Cramer breaks down the theme of stealth technology stocks. Cramer says companies that are using proprietary technology to invent entirely new markets and then dominate those markets, fall under that category.

  • Mad Money host Jim Cramer knows it can be difficult to stick with a stock that is going lower but says if you've done the homework, and the story isn't wildly off the rails, then stay long.

  • Mad Money host Jim Cramer, outlines the most common emotionally driven investor mistakes and expresses why it is important to not let skepticism run away with you.